Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States

Annals of Internal Medicine

Volumn 163, Issue 3, 2015, Pages 215-223

  Barua, Soumitri ^a   Greenwald, Robert ^b   Grebely, Jason ^c   Dore, Gregory J ^c   Swan, Tracy ^d   Taylor, Lynn E ^e  

^a BROWN UNIVERSITY   (United States)

^b HARVARD LAW SCHOOL   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Treatment Action Group   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANTIVIRAL THERAPY; CONSULTATION; DECOMPENSATED LIVER CIRRHOSIS; DRUG USE; ELASTOGRAPHY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MEDICAID; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SUBSTANCE ABUSE; UNITED STATES; URINALYSIS; ANALOGS AND DERIVATIVES; DRUG COST; ECONOMICS; HEALTH CARE POLICY; HEPATITIS C, CHRONIC; ORGANIZATION AND MANAGEMENT;

ANTIVIRAL AGENTS; DRUG COSTS; ELIGIBILITY DETERMINATION; HEALTH POLICY; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICAID; SOFOSBUVIR; UNITED STATES; URIDINE MONOPHOSPHATE;

EID: 84938795806     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0406     Document Type: Review

References (51)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-57. [PMID: 25086286] doi:10.1016/j.jhep.2014.07.027
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology. 2013;57: 1333-42. [PMID: 23172780] doi:10.1002/hep.26141
3. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31:331-9. [PMID: 22189973] doi:10.1055/s-0031-1297922
4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-62. [PMID: 23817321] doi:10.1038/nrgastro.2013.107
5. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93. [PMID: 23268517] doi:10.1001/jama.2012.144878
6. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50: 1750-5. [PMID: 19824079] doi:10.1002/hep.23220
7. Lettmeier B, Mu hlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol. 2008;49:528-36. [PMID: 18682313] doi:10.1016/j.jhep.2008.04.021
8. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-9. [PMID: 17005764]
9. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-65. [PMID: 25078309] doi:10.1016/S0140-6736(14) 61036-9
10. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-35. [PMID: 25614962] doi:10.1002/hep.27726
11. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-93. [PMID: 24725238] doi:10.1056/NEJMoa1316366
12. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al; POSITRON Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-77. [PMID: 23607593] doi:10.1056/NEJMoa1214854
13. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370: 1879-88. [PMID: 24720702] doi:10.1056/NEJMoa1402355
14. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87. [PMID: 23607594] doi:10.1056/NEJMoa1214853
15. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? [Editorial]. Hepatology. 2014;59: 1246-9. [PMID: 24493069] doi:10.1002/hep.27039
16. Centers for Medicare & Medicaid Services. Medicaid drug rebate program. Accessed at www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/medicaid-drug-rebate-program.html on 10 February 2015.
17. Henry J. Kaiser Family Foundation. State health facts: Medicaid income eligibility limits for adults as a percent of the federal poverty level. Menlo Park, CA: Henry J. Kaiser Family Foundation; 2015. Accessed at kff.org/health-reform/state-indicator/medicaid-income-eligibility-limits-for-adults-as-a-percent-of-the-federal-poverty-level on 8 April 2015.
18. Office of the Assistant Secretary for Planning and Evaluation; U.S. Department of Health and Human Services. 2015 poverty guidelines. Accessed at aspe.hhs.gov/poverty/15poverty.cfm on 8 April 2015.
19. 42 U.S.C. 1396r-8. Payment for covered outpatient drugs: requirements for formularies. Accessed at www.law.cornell.edu/uscode/text/42/1396r-8 on 9 June 2015.
20. 42 C.F.R. 440.230. Sufficiency of amount, duration, and scope. Accessed at www.law.cornell.edu/cfr/text/42/440.230 on 9 June 2015.
21. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Accessed at www.hcvguidelines.org on 18 January 2015.
22. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-207. [PMID: 21631316] doi:10.1056/NEJMoa1009370
23. Gilead Sciences. Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2014. Accessed at www.gilead.com/-/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf on 14 April 2015.
24. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230-6. [PMID: 23616492] doi:10.1093/cid/cit234
25. Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients coinfected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014; 160:369-79. [PMID: 24723077] doi:10.7326/M13-1829
26. Chen TY, Ding EL, Seage III GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49:1605-15. [PMID: 19842982] doi:10.1086/644771
27. Weber R, Sabin CA, Friis-Mller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166: 1632-41. [PMID: 16908797]
28. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol.2014;60:392-420.[PMID:24331294]doi:10.1016/j.jhep.2013.11.003
29. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353-61. [PMID: 25038354] doi:10.1001/jama.2014.7734
30. Kottilil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection: is it time for the internist to take the reins? Ann Intern Med. 2014;161:443-4. [PMID: 25222390] doi:10.7326/M14-0741
31. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S-9S. [PMID: 10653448]
32. U.S. Department of Health and Human Services; National Institutes of Health; NIH Consensus Development Program; Office of Disease Prevention. Management of Hepatitis C: 2002: National In- stitutes of Health consensus conference statement, 10-12 June 2002. Accessed at consensus.nih.gov/2002/2002hepatitisc2002 116html.htm on 19 December 2014.
33. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, et al; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S129-37. [PMID: 23884061] doi:10.1093/cid/cit302
34. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61: 373-95. [PMID: 24818984] doi:10.1016/j.jhep.2014.05.001
35. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection: April 2014. Accessedatapps. who.int/iris/bitstream/10665/111747/1/9789241548755-eng.pdf on 18 December 2014.
36. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-64. [PMID: 21371579] doi:10.1016/j.jhep.2011.02.023
37. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49:561-73. [PMID: 19589081] doi:10.1086/600304
38. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120-4. [PMID: 15239094]
39. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis. 2005;40 Suppl 5:S325-9. [PMID: 15768342]
40. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005;29:159-65. [PMID: 16183464]
41. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol. 2007;22:1519-25. [PMID: 17645460]
42. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al; Australian Trial In Acute Hepatitis C Study Group. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138:123-35.e1-2. [PMID: 19782085] doi:10.1053/j.gastro.2009.09.019
43. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57 Suppl 2:S80-9. [PMID: 23884071] doi:10.1093/cid/cit306
44. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55: 49-57. [PMID: 21898506] doi:10.1002/hep.24656
45. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol. 2007;41:761-72. [PMID: 17700425]
46. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol. 1996;91:498-505. [PMID: 8633498]
47. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol. 2005;3:1150-9. [PMID: 16271348]
48. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27:914-9. [PMID: 9537428]
49. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al; VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006; 130:1607-16. [PMID: 16697724]
50. Le Lan C, Guillygomarc'h A, Danielou H, Le Dréau G, Lainé F, Védeilhié C, et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol. 2012;56:334-40. [PMID: 21756854] doi: 10.1016/j.jhep.2011.05.021
51. Graham CS, Greenwald R, Lenz K. Understanding the reimbursement environment in hepatitis C. Presented at Massachusetts Department of Public Health, Boston, Massachusetts, 6 April 2015. Accessed at www.chlpi.org/wp-content/uploads/2014/01/HCV-DPH-Payer-4-5-15-combined-final.pdf on 8 June 2015.